Pandion Therapeutics Inc. (PAND) News
Filter PAND News Items
PAND News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PAND News Highlights
- PAND's 30 day story count now stands at 4.
- Over the past 2 days, the trend for PAND's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about PAND are PD and SA.
Latest PAND News From Around the Web
Below are the latest news stories about Pandion Therapeutics Inc that investors may wish to consider to help them evaluate PAND as an investment opportunity.
SHAREHOLDER ALERT: WeissLaw LLP Reminds FI, SVBI, FRPX, and PAND Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion AntibodyGENEVA--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, announced today that it has signed a service agreement with Pandion Therapeutics, Inc., to advance the development of Pandion’s PT627, a systemically-acting PD-1 agonist antibody for the potential treatment of autoimmune and inflammatory diseases. Under the terms of the agreement, Pandion will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to huma |
INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate CUB, PAND, CRHM, JCS; Shareholders Are Encouraged to Contact the FirmNEW YORK, NY / ACCESSWIRE / March 16, 2021 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:Cubic Corporation (NYSE:CUB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Veritas Capital and Evergreen Coast Capital Corporation. Under the terms of the merger agreement, Cubic shareholders will receive $70. |
SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following MergerJuan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: |
Lifshitz Law Firm, P.C. Announces Investigation of MDCA, FPRX, PAND, and PRSPNEW YORK, NY / ACCESSWIRE / March 14, 2021 /MDC Partners Inc. (NASDAQ:MDCA)Lifshitz Law Firm, P. |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates CMD, COHR, PRSP, CUB, PAND; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
Lifshitz Law Firm, P.C. Announces Investigation of APEX, CTB, FRTA, and PANDNEW YORK, NY / ACCESSWIRE / March 7, 2021 / Apex Global Brands, Inc. (OTC PINK:APEX) Lifshitz Law Firm, P. |
After three years of courtship (and turndowns), Merck pounced on the first glance of clinical data in $1.85B Pandion takeoverIt's almost become cliché for biotech executives to talk about the importance of keeping your options open and being prepared to go all the way. But when it comes to negotiating with a giant like Merck, a little patience can indeed go a long way. Just ask Pandion Therapeutics. Days |
SHAREHOLDER ALERT: WeissLaw LLP Reminds PAND, VKIN, CLGX, and VGAC Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Merck Begins Tender Offer to Acquire Pandion TherapeuticsKENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Begins Tender Offer to Acquire Pandion Therapeutics |